Metoprolol for the Prevention of Acute Exacerbations of COPD (BLOCK COPD)

Authors, Journal, Affiliations, Type, DOI

• Authors: M.T. Dransfield, H. Voelker, S.P. Bhatt, K. Brenner, R. Casaburi, C.E. Come, J.A.D. Cooper, G.J. Criner, J.L. Curtis, M.L.K. Han, U. Hatipoğlu, et al. (BLOCK COPD Trial Group)
• Journal: New England Journal of Medicine, December 12, 2019
• Affiliations: Led by University of Alabama at Birmingham; 26 centres across the United States
• Type: Prospective, double-blind, placebo-controlled randomised controlled trial
• Funding: Department of Defense (no commercial involvement)
• DOI: 10.1056/NEJMoa1908142

Overview

The BLOCK COPD trial randomised 532 patients with moderate-to-severe COPD (who did not have an established indication for beta-blockers) to extended-release metoprolol or placebo for approximately one year. The trial was stopped early for futility and safety: metoprolol did not reduce time to first exacerbation (202 vs 222 days; HR 1.05; p=0.66) and was associated with a significantly higher risk of hospitalisation for exacerbation (HR 1.91) and a numerically higher mortality (11 vs 5 deaths). These results directly contradict prior observational studies and meta-analyses suggesting beta-blockers reduce exacerbation risk and death in COPD, which are now understood to reflect residual confounding and immortal time bias.

Keywords

Beta-blockers, COPD, exacerbations, metoprolol, beta-blocker safety, BLOCK COPD, randomised controlled trial, cardioselective beta-blocker

Key Takeaways

Background and Rationale

• COPD is the third leading cause of death worldwide; exacerbations — especially hospitalisation-level — drive most morbidity, mortality, and cost.
• Patients with COPD have up to five times the cardiovascular disease risk of age-matched controls; cardiovascular disease is a risk factor for COPD exacerbations.
• Multiple observational studies and meta-analyses had suggested beta-blockers reduce both exacerbation risk and death in COPD patients (e.g., relative risk of COPD-related death 0.69 in one meta-analysis; another showed all-cause death RR 0.72). However, these observational data are subject to immortal time bias and residual confounding.
• Beta-blockers are also frequently withheld in COPD patients who have proven indications (e.g., post-MI, HFrEF), due to concern about adverse pulmonary effects — this practice persists despite observational evidence of safety.
• BLOCK COPD was the first adequately-powered RCT to prospectively test whether metoprolol prevents exacerbations in high-risk COPD patients without an established beta-blocker indication.

Study Design

• Design: Double-blind, placebo-controlled RCT; 26 US centres; May 2016–March 2019
• Inclusion: Age 40–85; clinical COPD diagnosis + FEV1 <80% predicted + FEV1/FVC <0.70; increased exacerbation risk (systemic glucocorticoids/antibiotics for respiratory problems, ED visit/hospitalisation for COPD exacerbation, or prescribed supplemental O2 in prior year); resting HR 65–120 bpm; resting SBP >100 mmHg
• Exclusion: Established beta-blocker indication (MI/revascularisation ≤36 months, HF with LVEF <40%); already taking a beta-blocker
• Intervention: Extended-release metoprolol succinate, starting 50 mg/day; dose adjusted over 42 days to 25, 50, or 100 mg/day based on HR, BP, FEV1, and side effects; followed by weaning
• Duration: Treatment period 336–350 days (dose-dependent); follow-up to day 378

Primary Endpoint

• Time to first COPD exacerbation of any severity: Metoprolol 202 days (95% CI 162–282) vs placebo 222 days (95% CI 189–295)
• Unadjusted HR 1.05 (95% CI 0.84–1.32; P=0.66); adjusted HR 1.12 (95% CI 0.88–1.42)
• Trial stopped early by DSMB for futility and safety concerns (March 2019)

Secondary Endpoints — Exacerbations

• Moderate+ exacerbations (ED or hospitalisation): Unadjusted HR 1.47 (95% CI 1.06–2.04); adjusted HR 1.46 (95% CI 1.03–2.06) — statistically significant harm
• Severe/very severe exacerbations (hospitalisation ± intubation): Unadjusted HR 1.91 (95% CI 1.29–2.83); adjusted HR 2.08 (95% CI 1.37–3.14) — highly significant harm
• Overall exacerbation rate: 1.40 vs 1.33/person-year (rate ratio 1.05; 95% CI 0.85–1.28; NS)
• Severe exacerbation rate: Rate ratio 1.51 (95% CI 1.00–2.29)
• Very severe exacerbation rate: Rate ratio 3.71 (95% CI 1.10–16.98)

Mortality

• Deaths during treatment period: 11 metoprolol vs 5 placebo (unadjusted HR 2.18; 95% CI 0.76–6.29; NS — likely underpowered but directionally concerning)
• Cause of death: 7 vs 1 attributed to COPD; proportionally much higher COPD-related mortality in metoprolol group
• After treatment period: 3 additional metoprolol deaths, 4 additional placebo deaths (total: 14 vs 9)

Hospitalization and Adverse Events

• All-cause hospitalisation rate: 0.66 vs 0.42/person-year in metoprolol vs placebo
• Nonfatal serious COPD exacerbations: 0.43 vs 0.19/person-year
• Patient-reported adverse events possibly related to metoprolol: No significant between-group difference in frequency
• Heart rate: Lower in metoprolol group by 6–10 bpm throughout trial

Symptom and Functional Outcomes

• FEV1: No significant between-group difference (reassuring — lung function not worsened by metoprolol)
• 6-minute walk distance: No significant between-group difference
• COPD Assessment Test (CAT score): Worse in metoprolol group — difference +1.13 pts (day 112) and +1.47 pts (day 336) — clinically meaningful (MCID 2 pts; close to threshold)
• San Diego Shortness of Breath Questionnaire (SOBQ): Worse in metoprolol group — difference +3.47 pts (day 112) and +4.80 pts (day 336) — exceeds MCID of 5 pts at day 336
• St. George's Respiratory Questionnaire: No significant between-group difference
• Discontinuation: 11.2% metoprolol vs 6.1% placebo; most common reason: increase in respiratory symptoms

Limitations of the Document

• Early stopping: Trial stopped before target enrolment (532/1028) → limited power for subgroup analyses and unable to identify predisposing factors for adverse outcomes
• Imperfect blinding: Beta-blockade physiological effects (HR reduction, BP lowering) detectable by patients/clinicians despite pill blinding
• Selected population: Only moderate-severe COPD with high exacerbation risk — results may not apply to mild COPD or lower-risk patients
• Drug-specific result: Only extended-release metoprolol tested; other cardioselective agents (bisoprolol, nebivolol) may have different effects; non-cardioselective agents expected to be worse
• Excluded established-indication patients: Results do not address whether BB worsens COPD exacerbations in patients who require BB for MI or HFrEF
• Predominantly US population: External generalisability uncertain

Key Concepts Mentioned

• concepts/HF-COPD-Comorbidity — BLOCK COPD provides the definitive RCT evidence that beta-blockers without established indication are harmful in COPD
• concepts/Beta-Blocker-Post-MI — metoprolol as the archetypal cardioselective BB; COPD-specific contraindication now RCT-confirmed in non-indicated patients

Key Entities Mentioned

• entities/COPD — primary disease studied; exacerbation prevention as endpoint; metoprolol harmful in non-indicated COPD
• entities/Metoprolol — drug under study; extended-release formulation; dose 25–100 mg/day

Wiki Pages Updated

• wiki/sources/metoprolol-block-copd-nejm-2019.md — created (this file)
• wiki/entities/COPD.md — added BLOCK COPD key findings, updated beta-blocker section and contradictions
• wiki/concepts/HF-COPD-Comorbidity.md — added BLOCK COPD trial data under beta-blocker treatment section and contradictions
• wiki/concepts/Beta-Blocker-Post-MI.md — added COPD caveat section
• wiki/sourceindex.md — updated
• wiki/wikiindex.md — updated